Concomitant Treatment of Malignant Brain Tumours With CBD – A Case Series and Review of the Literature.

Authors: Rudolf Likar, Markus Koestenberger, Martin Stultschnig, Gerhard Nahler
Anticancer Research, October 2019

Grade IV glioblastoma multiforme is a deadly disease, with a median survival of around 14 to 16 months. Maximal resection followed by adjuvant radiochemotherapy has been the mainstay of treatment since many years, although survival is only extended by a few months. In recent y…

Current natural therapies in the treatment against glioblastoma.

Authors: José Ignacio Erices, Ángelo Torres, Ignacio Niechi, Isabel Bernales, Claudia Quezada
Phytotherapy Research, November 2018

Glioblastoma (GBM) is the most common and aggressive brain tumor, which causes the highest number of deaths worldwide. It is a highly vascularized tumor, infiltrative, and its tumorigenic capacity is exacerbated. All these hallmarks are therapeutic targets in GBM treatment, in…

A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma

Authors: Susan Short, Christopher Twelves, Lucy Brazil, Catherine McBain, et al, 11 August 2016

An open-label phase to assess the frequency and severity of adverse events in recurrent glioblastoma patients receiving Sativex in combination with dose-intense Temozolomide (Part A). A randomisation phase to assess the safety of Sativex compared with placebo (Part B). Patient…

Targeting endocannabinoid signaling in tumor‐associated macrophages as treatment for glioblastoma multiforme

Authors: Susan Fung, Nephi Stella
Wiley Interdisciplinary Reviews: Membrane Transport and Signaling, 21 January 2014

Glioblastoma multiforme (GBM) is the most common form of primary brain tumor and is diagnosed in approximately 15,000 people each year in the United States alone. No cure for this type of cancer exists, and the current standard of care treatments provide little benefit and are…

Primary gliosarcoma of the brain: radiologic and histopathologic features.

Authors: Alfredo E. Romero-Rojas, Julio A. Diaz-Perez, Lina M. Ariza-Serrano, et al
The Neuroradiology Journal, December 2013

Gliosarcoma is a rare central nervous system (CNS) neoplasm with biphasic glial and non-glial malignant components. Here we describe the radiologic and histopathologic features observed in five cases of primary gliosarcoma. The mean age at diagnosis in the studied patients was…

Spontaneous regression of septum pellucidum/forniceal pilocytic astrocytomas–possible role of Cannabis inhalation.

Authors: Mansoor Foroughi, Glenda Hendson, Michael A. Sargent, Paul Steinbok
Child’s Nervous System, DATE

INTRODUCTION: Spontaneous regression of pilocytic astrocytoma after incomplete resection is well recognized, especially for cerebellar and optic pathway tumors, and tumors associated with Neurofibromatosis type-1 (NF1). The purpose of this report is to document spontaneous reg…

A combined preclinical therapy of cannabinoids and temozolomide against glioma.

Authors: Sofía Torres, Mar Lorente, Fátima Rodríguez-Fornés, Sonia Hernández-Tiedra, et al
Molecular Cancer Therapeutics, January 2011

Glioblastoma multiforme (GBM) is highly resistant to current anticancer treatments, which makes it crucial to find new therapeutic strategies aimed at improving the poor prognosis of patients suffering from this disease. Δ(9)-Tetrahydrocannabinol (THC), the major active ingred…

Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival.

Authors: Jahan P. Marcu, Rigel T. Christian, Darryl Lau, Anne J. Zielinski, Maxx P. Horowitz, et al
Molecular Cancer Therapeutics, January 2010

The cannabinoid 1 (CB(1)) and cannabinoid 2 (CB(2)) receptor agonist Delta(9)-tetrahydrocannabinol (THC) has been shown to be a broad-range inhibitor of cancer in culture and in vivo, and is currently being used in a clinical trial for the treatment of glioblastoma. It has bee…

Cannabinoid receptors in human astroglial tumors.

Authors: Janka Held‐Feindt, Lutz Dörner, Gülcan Sahan,H. Maximilian Mehdorn, Rolf Mentlein
Journal of Neurochemistry, August 2008

In animal models, cannabinoids are reported to inhibit the growth of tumors, including gliomas. These effects have been claimed to be mediated via cannabinoid receptors 1 and 2 (CB1, CB2). To elucidate a possible relevance for treatment of human gliomas, we investigated recept…

Cannabinoids for cancer treatment: progress and promise.

Authors: Sami Sarfaraz, Vaqar M. Adhami, Deeba N. Syed, Farrukh Afaq, Hasan Mukhtar
Cancer Research, 15 January 2008

Cannabinoids are a class of pharmacologic compounds that offer potential applications as antitumor drugs, based on the ability of some members of this class to limit inflammation, cell proliferation, and cell survival. In particular, emerging evidence suggests that agonists of…

A pilot clinical study of Delta9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme.

Authors: M. Guzmán, M. J. Duarte, C. Blázquez, J. Ravina, M. C. Rosa, I. Galve-Roperh, et al
British Journal of Cancer, 17 July 2006

Delta(9)-Tetrahydrocannabinol (THC) and other cannabinoids inhibit tumour growth and angiogenesis in animal models, so their potential application as antitumoral drugs has been suggested. However, the antitumoral effect of cannabinoids has never been tested in humans. Here we…